

**Supplementary table. Demographic characteristics, SARS-CoV-2 serological results and total immunoglobulin levels by disease-modifying therapy (DMT) group (no DMT, DMT other than anti-CD20, anti-CD20)**

	No DMT	DMT other than anti-CD 20	Anti-CD20
Number	21	77	21
Age, mean (SD)	49.3 (11.0)	41.2 (10.5)	43.5 (13.3)
Sex ratio (F/M)	14/7	58/19	16/5
EDSS, median (range)	2.5 (0-6)	1.5 (0-8)	4 (0-6.5)
Delay from COVID-19 (months), mean (SD)	5.4 (3.7)	5.1 (3.5)	4.2 (3.1)
<b>SARS-COV2 serology</b>			
	20		
- IgG antiS positivity, n (%)	(95.2%)	65 (84.4%)	8 (38.1%)
- IgG anti-S titre (log UA/mL), mean (SD)	2.7 (0.8)	2.4 (1.1)	1.4 (1.6)
	15		
- IgA anti-S positivity, n (%)	(71.4%)	50 (65%)	7 (33.3%)
- IgA anti-S index, mean (SD)	2.4 (3.2)	1.9 (1.9)	1.1 (0.5)
	17		
- IgG anti-N positivity, n (%)	(80.9%)	56 (72.7%)	3 (14.3%)
- IgG anti-N Index, mean (SD)	2.7 (2.5)	2.2 (2.2)	0.5 (1.0)
Total IgG (g/L), mean (SD)	10.4 (2.7)	11.0 (2.8)	9.1 (2.0)
Total IgA (g/L), mean (SD)	2.2 (0.8)	1.9 (0.8)	1.9 (1.0)
Total IgM (g/L), mean (SD)	1.3 (0.8)	1.2 (0.8)	0.8 (0.4)